Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 8Leukemia, Myeloid, Chronic-Phase 7Burkitt Lymphoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Philadelphia Chromosome 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1

Interventions

Radiosurgery 50Magnetic Resonance Spectroscopy 34Temozolomide 28Bevacizumab 24pembrolizumab 23Radiotherapy 20Nivolumab 20Specimen Handling 14Ipilimumab 13Cyclophosphamide 13Mental Status and Dementia Tests 12Carboplatin 12abemaciclib 10Radiation 10trastuzumab deruxtecan 8Proton Therapy 7Pemetrexed 7Memantine 7Blood Specimen Collection 7fluciclovine F-18 6binimetinib 6Paclitaxel 6Lomustine 6Etoposide 6Cisplatin 6Capecitabine 6encorafenib 5Trastuzumab 5Surveys and Questionnaires 5Surgical Procedures, Operative 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Dasatinib × 1 year × Clear all
NCT02389309 2026-03-09

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
14 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡